GHRH Antagonists Inhibit Prostate Cancer by Modulating p53 Tumor Suppressor

Prostate cancer remains a significant health challenge, with a pressing need for novel therapeutic strategies. Growth hormone-releasing hormone (GHRH) and its receptors are frequently overexpressed in various malignancies, including prostate cancer, suggesting their involvement in tumor proliferation and progression. This study aimed to investigate how GHRH antagonists influence key cellular pathways, specifically the p53 tumor suppressor pathway, in experimental prostate cancers.

The administration of GHRH antagonists demonstrated significant inhibitory effects on the proliferation and progression of experimental prostate cancers. The most striking and important finding was a clear upregulation of wild-type p53 protein, a critical tumor suppressor responsible for regulating cell division and inducing apoptosis (programmed cell death), indicating a restoration of normal cellular control mechanisms. Concurrently, the study observed a notable decrease in p21 protein, which typically halts the cell cycle, and a decrease in mutant p53 proteins, which can promote uncontrolled cell growth and resistance to therapy. This dual action suggests that GHRH antagonists not only boost beneficial tumor suppressors but also reduce factors that contribute to cancer progression, leading to a substantial anti-cancer effect compared to untreated controls.